AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
Latest, Q2 2026
2,316
Period ended Jun 30, 2026
Change on a year earlier
+9.6%
2,113 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
39
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Work in Process ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 2,316 | +9.6% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2026 | Mar 31, 2026 | 2,137 | +8.3% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 2,287 | +17.2% | Form 10-Q (filed 2026-08-03) ↗ |
| Q3 2025 | Sep 30, 2025 | 2,277 | +9.9% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 2,113 | +9.5% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,974 | +4.4% | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,951 | +18.7% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 2,071 | +22.5% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,930 | +20.2% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,890 | +44.1% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,643 | +15.9% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2023 | Sep 30, 2023 | 1,690 | +29.1% | Form 10-Q (filed 2023-11-06) ↗ |
| Q2 2023 | Jun 30, 2023 | 1,606 | +28.5% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 1,312 | +6.2% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2022 | Dec 31, 2022 | 1,417 | +18.8% | Form 10-K (filed 2024-02-20) ↗ |
| Q3 2022 | Sep 30, 2022 | 1,309 | -1.4% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2022 | Jun 30, 2022 | 1,250 | -8.9% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 1,235 | +1.7% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 1,193 | -0.7% | Form 10-K (filed 2023-02-17) ↗ |
| Q3 2021 | Sep 30, 2021 | 1,328 | +2.5% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 1,372 | +0.7% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2021 | Mar 31, 2021 | 1,214 | +30.3% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2020 | Dec 31, 2020 | 1,201 | +27.5% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2020 | Sep 30, 2020 | 1,295 | +15.6% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 1,363 | +40.7% | Form 10-Q (filed 2020-08-04) ↗ |
| Q1 2020 | Mar 31, 2020 | 932 | +5.9% | Form 10-Q (filed 2020-05-08) ↗ |
| Q4 2019 | Dec 31, 2019 | 942 | +9.3% | Form 10-K (filed 2021-02-19) ↗ |
| Q3 2019 | Sep 30, 2019 | 1,120 | +6.3% | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2019 | Jun 30, 2019 | 969 | +4.9% | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 880 | -3.6% | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2018 | Dec 31, 2018 | 862 | +4.9% | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2018 | Sep 30, 2018 | 1,054 | -17.1% | Form 10-Q (filed 2018-11-07) ↗ |
| Q2 2018 | Jun 30, 2018 | 924 | -12.4% | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2018 | Mar 31, 2018 | 913 | -10.8% | Form 10-Q (filed 2018-05-04) ↗ |
| Q4 2017 | Dec 31, 2017 | 822 | -23.9% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2017 | Sep 30, 2017 | 1,271 | +7.3% | 10-Q FY2017 (XBRL) ↗ |
| Q2 2017 | Jun 30, 2017 | 1,055 | -1.2% | 10-Q FY2017 (XBRL) ↗ |
| Q1 2017 | Mar 31, 2017 | 1,024 | -5.4% | 10-Q FY2017 (XBRL) ↗ |
| Q4 2016 | Dec 31, 2016 | 1,080 | -0.1% | Form 10-K (filed 2018-02-16) ↗ |
| Q3 2016 | Sep 30, 2016 | 1,184 | +11.4% | 10-Q FY2016 (XBRL) ↗ |
| Q2 2016 | Jun 30, 2016 | 1,068 | +4.8% | 10-Q FY2016 (XBRL) ↗ |
| Q1 2016 | Mar 31, 2016 | 1,082 | +90.5% | 10-Q FY2016 (XBRL) ↗ |
| Q4 2015 | Dec 31, 2015 | 1,081 | – | Form 10-K (filed 2017-02-17) ↗ |
| Q3 2015 | Sep 30, 2015 | 1,063 | – | 10-Q FY2015 (XBRL) ↗ |
| Q2 2015 | Jun 30, 2015 | 1,019 | – | 10-Q FY2015 (XBRL) ↗ |
| Q1 2015 | Mar 31, 2015 | 568 | – | 10-Q FY2015 (XBRL) ↗ |
Cite this data
StockData. (2026). AbbVie Work in Process ($M) ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/inv_wip
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.